Last edition
News about "Zealand Pharma "
Zealand Pharma Signs USD 100 Million Royalty Deal with Royalty Pharma for Rusfertide
Zealand Pharma will receive USD 100 million from Royalty Pharma for its rusfertide economic interests, unlocking value from royalty rights for strategic investments.
Zealand Pharma | 13/08/2026 | By News Bureau
Zealand Pharma and Roche to Develop and Commercialize Petrelintide
The two companies will co-develop and co-commercialize petrelintide and combination products with petrelintide, including a fixed-dose combination product of petrelintide and CT-388, Roche’s lead incretin asset and potential best-in-class GLP-1/GIP receptor dual agonist.
Zealand Pharma | 15/03/2025 | By Aishwarya | 436
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy